Hematopoietic stem cell transplantation (HSCT) is an established therapeutic intervention for a variety of haematological malignancies and non-malignant disorders. Central to the success of HSCT is ...

Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...

Biomarker testing and patient demographic disparities among breast cancer patients across treatment settings. Sociodemographic and clinical determinants of survival in metastatic breast cancer: A ...

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Primarily, the transplantation from a ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...

Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform ...

ORLANDO -- Stem-cell transplants with mismatched unrelated donors (MMUDs) beyond a single HLA locus (<7/8) had 1-year survival similar to better-matched donors, suggesting significant potential to ...

HLAs sit on the surface of cells and have enormous variability from person to person, serving somewhat as molecular fingerprints. When the body encounters unfamiliar versions of these proteins from a ...